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Abstract
Background
An increased prevalence of epilepsy has been reported in many onchocerciasis endemic
areas. The objective of this study was to determine the prevalence of epilepsy in onchocerci-
asis endemic areas in the Democratic Republic of the Congo (DRC) and investigate whether
a higher annual intake of Ivermectin was associated with a lower prevalence of epilepsy.
Methodology/Principle findings
Between July 2014 and February 2016, house-to-house epilepsy prevalence surveys were
carried out in areas with a high level of onchocerciasis endemicity: 3 localities in the Bas-
Uele, 24 in the Tshopo and 21 in the Ituri province. Ivermectin uptake was recorded for
every household member. This database allowed a matched case-control pair subset to be
created that enabled putative risk factors for epilepsy to be tested using univariate logistic
regression models. Risk factors relating to onchocerciasis were tested using a multivariate
random effects model. To identify presence of clusters of epilepsy cases, the Kulldorff’s
scan statistic was used. Of 12, 408 people examined in the different health areas 407
(3.3%) were found to have a history of epilepsy. A high prevalence of epilepsy was observed
in health areas in the 3 provinces: 6.8–8.5% in Bas-Uele, 0.8–7.4% in Tshopo and 3.6–6.2%
in Ituri. Median age of epilepsy onset was 9 years, and the modal age 12 years. The case
control analysis demonstrated that before the appearance of epilepsy, compared to the
same life period in controls, persons with epilepsy were around two times less likely (OR:
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0.52; 95%CI: (0.28, 0.98)) to have taken Ivermectin than controls. After the appearance of
epilepsy, there was no difference of Ivermectin intake between cases and controls. Only in
Ituri, a significant cluster (p-value = 0.0001) was identified located around the Draju sample
site area.
Conclusions
The prevalence of epilepsy in health areas in onchocerciasis endemic regions in the DRC
was 2–10 times higher than in non-onchocerciasis endemic regions in Africa. Our data sug-
gests that Ivermectin protects against epilepsy in an onchocerciasis endemic region. How-
ever, a prospective population based intervention study is needed to confirm this.
Author summary
An increased prevalence of epilepsy has been reported in many onchocerciasis endemic
areas. Between July 2014 and February 2016, house-to-house epilepsy prevalence surveys
were carried out in the Bas-Uele, Tshopo and Ituri province of the Democratic Republic
of the Congo, in areas with a high level of onchocerciasis endemicity. Of 12, 408 people
examined in the different health areas 407 (3.3%) were found to have a history of epilepsy.
A nested case control analysis demonstrated that before the appearance of epilepsy, com-
pared to the same life period in controls, persons with epilepsy were around two times less
likely to have taken Ivermectin than controls. Our data suggests that Ivermectin protects
against epilepsy in an onchocerciasis endemic region. However, a prospective population
based intervention study is needed to confirm this.
Introduction
A high prevalence of epilepsy (>1%) has been reported in many onchocerciasis endemic
regions. In Africa, a special form of epilepsy referred to as “nodding syndrome” has been
reported solely in onchocerciasis endemic areas [1]. The Democratic Republic of the Congo
(DRC) is the country with the largest population at risk for onchocerciasis, with approximately
40.3 million people exposed and 29.7 million currently treated [2,3]. In the DRC, despite 16
years of Community Directed Treatment with Ivermectin (CDTI), the therapeutic coverage of
Ivermectin is not consistent spatially or from year to year, and some areas remain untreated
(have received no CDTI at all). According to the WHO, the geographic coverage for the coun-
try in 2007 was 72.2% and the therapeutic coverage 43.5% and in 2015, 93.3% and 73.3%
respectively [3,4]. The inconsistent therapeutic coverage combined with the high level of
onchocerciasis endemicity, may thus have direct consequences for the epilepsy prevalence in
endemic areas in the DRC. In 2014, we documented the prevalence of epilepsy to be 2.9% in
the village of Dingila and 2.3% in Titule, both in the Bas-Uele province [5]. In Titule, epilepsy
showed a marked spatial pattern with clustering of cases occurring within and between adja-
cent households. Individual risk of epilepsy was found to be associated with living close to the
nearest fast flowing river where blackflies (Diptera: Simuliidae)–the vector of Onchocerca vol-
vulus (O.v)–oviposit and breed [5]. A small case control study in Titule suggested that Ivermec-
tin may protect against onchocerciasis associated epilepsy or OAE [6].
Epilepsy in onchocerciasis endemic regions in the Democratic Republic
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In this study, we investigated in door-to-door village surveys whether there was increased
epilepsy prevalence in other onchocerciasis endemic foci of the DRC, in the provinces of Bas-
Uele, Tshopo and Ituri (previously part of the “Oriental Province”). Moreover, in a nested case
control study we examined whether there was evidence for annual intake of Ivermectin being
able to provide significant protection against epilepsy.
Materials and methods
Definition: A case of epilepsy was defined as a patient who reported at least 2 unprovoked sei-
zures without fever or any acute illness [7].
Estimation of the epilepsy prevalence
Between July 2014 and February 2016, house-to-house epilepsy prevalence surveys were car-
ried out in 3 localities of Bas-Uele covering 164 households, 24 localities of Tshopo covering
1322 households and 19 localities of Ituri province covering 570 households (Fig 1).
The localities were selected on the basis of a historically high level of onchocerciasis
endemicity based on Rapid Epidemiological Monitoring of Onchocerciasis (REMO) (1998 or
2003) data provided by the National Onchocerciasis control program (Programme National
de Lutte contre l’Onchocercose, PNLO) [8]. In Ituri localities within one health area were cho-
sen because they had never been included in the CDTI program and as such never received
Ivermectin.
In the three provinces, houses were selected starting from the localities centres’, selecting
every third household. If household members of the selected house were not at home, the next
house was visited; all households were geo-located (handheld Garmin 62Cs GPS; ±4m accu-
racy). This method was implemented in all study sites except in the Tshopo province, in the
Wanierukula health zone, where all houses on a 40km stretch of the national road linking
Kisangani (Tshopo province) to the Ituri province were visited. The latter region is referred to
as the “PK30-PK70” region (as it does not exist, administratively) and contains 1182 unique
households across 2 health areas consisting of 14 localities. In every area, all household heads
and parents of children present in the household were interviewed in their local language. For
every consenting household, a one page questionnaire was completed (available as supporting
information). Age and sex of every household member and their individual history of Ivermec-
tin uptake each year between 2000–2015 were recorded. Screening for epilepsy was performed
using the five questions questionnaire validated by Diagana et al [9]. The research team who
visited the households consisted of one or two local health care workers or Ivermectin commu-
nity distributers and a medical doctor. If a person with epilepsy was identified, family members
were asked by a doctor to describe the type of seizures (or to show what happens during a sei-
zure), to report on the precipitant circumstances, the duration of seizures, whether they were
associated with uncontrollable tongue biting or passing of urine or stool, whether there were
episodes of absence (sudden episodes of decreased consciousness of sudden onset and short
duration) with or without nodding of the head. Questions were asked in the local language
Boa, Lingala, Kiswahili or Lendu according to the site. The final diagnosis of epilepsy was
made by a medical doctor.
For household members with epilepsy confirmed by the doctor, the age of the first epilepsy
episode was noted. For those who developed epilepsy recently, the exact month of the first epi-
lepsy attack was recorded. Onset of epilepsy was considered recent if a first seizure appeared in
the 12 months before the survey date.
The prevalence of epilepsy in the populations surveyed was calculated across selected health
areas of the three provinces (Ituri, Tshopo, and Bas-Uele). The data on the prevalence of skin
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onchocerciasis lesions (leopard skin) and therapeutic coverage were obtained through house-
hold interviews. The prevalence of people with onchocerciasis nodules (determining the level
of onchocerciasis endemicity) were either obtained from the PNLO database or measured in
the field using the standard REMO procedure [8]. The number of years of Ivermectin distribu-
tion in each health area was also obtained from the PLNO database. Ivermectin coverage per
health area was calculated as the number of individuals in the health are who reported to have
taken Ivermectin in 2014 over the number of individuals eligible to receive Ivermectin in that
year. As eligibility criterium for Ivermectin treatment we only used age> 5 years old; we did
not took into account whether a women was pregnant or breast feeding.
Factors associated with epilepsy
Case control pairs were generated from individuals in the prevalence survey database by
matching individuals from the same health area, of the same gender and birth year. In this case
control sub-study, only cases were included who were old enough to be eligible for Ivermectin
distribution the year before they became epileptic (at least 6 years old at epilepsy appearance),
and who lived in health areas where Ivermectin was distributed under the CDTI program in
the year before they became epileptic.
Univariate binomial logistic mixed regression models were constructed to identify whether
there was an association between the epilepsy status and the individual Ivermectin treatment
history. A random effect term was included for pair identity. For cases (persons with epilepsy),
this was considered as Ivermectin treatment in the year immediately before epilepsy was
Fig 1. Location of the study sites in the former Oriental Province of the Democratic Republic of the
Congo.
https://doi.org/10.1371/journal.pntd.0005732.g001
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identified, and the proportion of years where Ivermectin was received in the years before and
after the reported onset of epilepsy. For controls (persons without epilepsy) the Ivermectin his-
tory was considered similarly, around the age at which their paired case became epileptic.
The association between epilepsy and potential risk factors, including the proportion of
Ivermectin doses received on occasions where the individual was eligible and the presence of
onchocerciasis-associated skin lesions, was assessed through the construction of a binomial
logistic mixed regression model using the whole survey data base, without case control pairing.
Age and gender were controlled for as categorical fixed effects, and the health area included as
a random effect to control for clustering at this level.
Spatial distribution
To identify presence of clusters of epilepsy cases, the Kulldorff’s scan statistic [10] as imple-
mented in SaTScan software (https://www.satscan.org/) was used. The spatial scan statistic
tests for spatial randomness of cases over the identified region. It defines a set of potential
cluster areas (spatial circles of varying size), each consisting of a collection of cases. The most
“unusual” cluster is then identified using the likelihood ratio test statistic which is based on the
alternative hypothesis that the risk of the disease is greater inside than outside the circle. The
most likely cluster is the circle with the maximum likelihood. For the epilepsy dataset, cases
were defined as individuals with epilepsy while controls are those without epilepsy. The Kul-
dorff’s scan statistic was performed for each of the three administrative regions separately:
Ituri, Tshopo and Bas-Uele province.
Software
All statistical analyses (aside from the scan statistic above) were implemented using the R sta-
tistical computing environment [11]. The generalized linear mixed model was implemented
using the package “lme4” [12].
Ethics statement
The study was approved by the Institutional Review Board of Ngaliema hospital in Kinshasa
and the ethical review board of the University of Antwerp. Written informed consent was
obtained from the head of the family and parents/guardians of children. For people who could
not write, consent was obtained by finger printing.
Results
Of the 12,408 people examined in the different health areas, 407 (3.3%) were found to have a
history of epilepsy. Across the localities, the mean number of household members was 5.65
(s.d. = 3.35). Whilst the median ages of the persons with epilepsy (18 years, IQR = 13, 23.75)
and without epilepsy (16 years, IQR = 6, 35) were relatively similar, the age distributions of the
persons with and those without epilepsy were significantly different (Two Sample Kolmogo-
rov-Smirnov test, D = 0.26, P<0.001) (Fig 2).
The median age of onset of epilepsy was 9 years; the modal age of onset was 12 years. The
highest prevalence of epilepsy was observed in the 10–19 years age group (Table 1).
Epilepsy appeared most frequently in the 10–15 year age group (Fig 3).
In 41 families there were at least 2 persons with epilepsy (1.5% of all households), and in 9
families at least three (0.3% of all households). Amongst the persons with epilepsy, 30% (123)
lived in households with another person with epilepsy. All persons with epilepsy had experi-
enced seizures in the last 5 years.
Epilepsy in onchocerciasis endemic regions in the Democratic Republic
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A high prevalence of epilepsy was observed in all health areas in the 3 provinces: 6.8–8.5%
in Bas-Uele, 0.8–7.4% in Tshopo and 3.6–6.2% in Ituri (Table 2).
Ninety six cases and controls perfectly matched for village, age and gender were identified
(Table 3).
Within the case control pairs, before the appearance of epilepsy, compared to the same life
period in controls, persons with epilepsy had taken less frequently Ivermectin than controls
(Table 4).
After the appearance of epilepsy, there was no difference of Ivermectin intake between
cases and controls.
Using the whole survey database, male gender, onchocerciasis skin lesions and being
treated, at least once with Ivermectin, were associated with a significantly higher risk of being
a person with epilepsy (Table 5).
Among the patients without leopard skin, those who used Ivermectin were twice as likely
(OR = 2.04) to have epilepsy as compared to those who did not use Ivermectin. However,
among the patients with leopard skin, thus showing signs of onchocerciasis, those who used
Ivermectin were 84% less likely (OR = 0.16) to have epilepsy than those who did not use
Ivermectin.
Fig 2. Histograms showing the distribution of ages in persons without (left) and with epilepsy (right).
https://doi.org/10.1371/journal.pntd.0005732.g002
Table 1. Age-specific prevalence rates of epilepsy.
Age (years) Population Number of patients with epilepsy Epilepsy prevalence (%)
> 40 2411 12 0.5%
30–39 1421 47 3.3%
20–29 1600 105 6.6%
10–19 2665 205 7.7%
< 10 4269 37 0.9%
All ages 12,366* 406* 3.3%
*42 individuals (of which one with epilepsy) had no age recorded and so are excluded.
https://doi.org/10.1371/journal.pntd.0005732.t001
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With regard to clustering of epilepsy cases, based on the Kulldorff scan statistics, 5 most
likely clusters of epilepsy cases were detected in Ituri, 9 in Tshopo and 2 in Bas-Uele. However,
most identified clusters had non-significant p-value (>0.1). In fact, of the 2 most likely clus-
ters, one in Ituri and the other one in Tshopo (Fig 4), only one had p-value less than 0.05.
The cluster in Ituri had p-value of 0.0001 with a radius of 1.41 km and is located around the
Draju sample site area with the Muda and Kuda rivers as nearest potential Simulid breeding
sites; however the local vector remains to be identified. On the other hand, the cluster in
Tshopo had p-value of 0.085 with a radius of 2.43 km and is located in between the Makana
and Salambongo sample sites close to the Mobi and Onane rivers where members of the Simu-
lium neavei complex were found on crabs. The most northern cluster in the Tshopo Province
is located around the Tshopo rivers where Simulium damnosum s.s. were aggressively biting
the villagers at the time of the study (data on blackflies exposure per province to be published
elsewhere).
Discussion
The observed prevalence of epilepsy in communities of onchocerciasis endemic regions in the
DRC was comparable with those reported in other onchocerciasis endemic areas in Africa [14]
but higher than the epilepsy prevalence (0.4–1%) reported in most studies in the rest of the
world [15–19]. In a study of 586,607 residents in five Health and Demographic Surveillance
System centres in sub-Saharan Africa, only 1,711 (0.29%) individuals were diagnosed as having
active convulsive epilepsy [20]. However, we did observe large differences in the prevalence of
epilepsy in different health areas, although the causes of these differences were not easy to
explain. The localities involved in this study were spread across a large geographical (and
Fig 3. Histogram of age of epilepsy onset.
https://doi.org/10.1371/journal.pntd.0005732.g003
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ecological) range, which is likely to encompass different levels of risk of exposure to the black-
fly vector. In the Ituri province, the prevalence of epilepsy was higher in the village where Iver-
mectin had never been distributed. In Aketi on the other hand, despite 13 years of CDTI and
a relatively high coverage of Ivermectin, the prevalence and incidence of epilepsy and the
Table 2. Prevalence rates of epilepsy, onchocerciasis (O.v.) endemicity, years of Ivermectin distribution and Ivermectin coverage in the surveyed
health areas of Bas-Uele, Tshopo and Ituri Provinces.
Province Health Zone Health Area Population
Surveyed
Epilepsy
prevalence
Epilepsy of
recent onset1
O.v.
nodules
O.v. skin
lesions6
Years of
Ivermectin
distribution
Ivermectin
coverage
20147
Ituri Logo Draju 1062 66 (6.2%) 6 (1.0%) 17/52
(32%)2
5 (0.5%) 0 0%
Rethy Rassia 898 32 (3.6%) 3 (0.3%) 15/49
(30.6%)2
2 (0.2%) 3 649/739
(87.8%)
Lokpa 843 31 (3.7%) 3 (0.4%) 5/50
(10%)2*
0.0% 3 524/718
(73.0%)
Tshopo Yahuma Mombongo 1260 26 (2.1%) 2 (0.2%) 57%3* 1 (0.1%) 10 312/945
(33.0%)
Tshopo Makutano
Pumuzikia
203 15 (7.4%) 2 (1.0%) 94%4* 4 (2.0%) 9 26/148
(17.6%)
Yaleko Yatange 424 11 (2.6%) 1 (0.2%) 67%4* 17 (4.0%) 4 12/342
(3.5%)
Wanierukula
(PK30-PK70)
Salambongo 5657 147 (2.6%) 9 (0.2%) 8/43
(18.6%)2
104 (1.9%) 10 601/4182
(14.4%)
Makana 1121 9 (0.8%) 0% 55%4* 5 (0.4%) 10 112/826
(13.6%)
Bas-Uele Aketi Wela 570 39 (6.8%) 6 (1.1%) 98%5* 55 (9.6%) 13 298/458
(65.1%)
Makoko 367 31 (8.4%) 5 (1.4%) 98%5* 12 (3.3%) 13 217/278
(78.1%)
1) Onset of seizures in the last 12 months
2) REMO data in September 2015 by our research team
*data obtained from the PLNO
3) RAPLOA, 2005.
4) RAPLOA, 2003
5) REMO, 1999 [13]
6) Only Leopard type of skin lesions were considered as O.v. skin lesions.
7) Number of individuals who reported to have taken Ivermectin in 2014/individual eligible to receive Ivermectin (%).
https://doi.org/10.1371/journal.pntd.0005732.t002
Table 3. Health zone and area distribution of case control sample.
Health Area Number of case control pairs from this health area
Rassia 4
Lokpa 5
Mombongo 4
Salambongo 35
Makana 4
Wela 21
Makoko 14
Yatange 2
Makutano Pumuzikia 7
Total number of pairs 96
https://doi.org/10.1371/journal.pntd.0005732.t003
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prevalence of onchocerciasis skin lesions was high. Wela is a village situated only 100m from
the Agu rapids on the Itimbiri river, a historically known Simulium damnosum breeding site.
In 1999, in Wela, before the introduction of CDTI, 98% of the men examined presented with
onchocerciasis nodules (REMO). A high S. damnosum density was observed in Aketi in 2016,
but we did not investigate the infection rate of the flies. It would be important to investigate
whether in the past in the Aketi health zone, the Iverrmectin therapeutic coverage has been
much lower than the one reported in 2014. In this health zone, we plan qualitative research to
obtain information about the adherence to the annual CDTI program and a case control study
to investigate whether other parasitic infections such as cysticercosis could explain the high
prevalence of epilepsy. Alternative hypotheses may be i) that in this health zone, the population
of O.v. may have developed Ivermectin resistance, ii) a higher vectorial capacity of S. damno-
sum sensu stricto compared to other vectors (unidentified so far in the Ituri province and S.
damnosum-complex in Tshopo province), iii) higher density of infective vector and hence an
increased level of exposure to Simuliidae infective bites. The infestation rate of the Simulium
spp. in the three foci would help answering some of these questions.
The peak incidence of epilepsy in patients in this study was around the age of 12. This aligns
with other onchocerciasis endemic African regions, and can most likely be explained by the
equally high incidence of O.v. infection in these age groups and the cumulative nature of the
O.v. infestation [21]. This peak incidence is in contrast with the epilepsy situation in industrial-
ized countries and in non-onchocerciasis endemic regions in Africa where most onset of epi-
lepsy is observed in the very young (< 5 years old) and in the older population [21]. It is
important to note that not only was there a high prevalence of epilepsy in the 10–19 age group,
but also in the 20–29 age group. The latter is in contrast with the epilepsy prevalence reported
in onchocerciasis hyperendemic regions where Ivermectin has not yet been introduced. For
example, in a study from 1991 in Kyarusozi sub-county in western Uganda, 91% of the epi-
lepsy cases were below the age of 19 [22]. This epilepsy age shift towards older age groups after
several years of annual Ivermectin distribution is an argument that Ivermectin may reduce the
incidence of epilepsy in children [23].
Around a third of the persons with epilepsy lived in a household with at least one other
person with epilepsy. In a study in Europe, only 9.5% of persons with epilepsy had first- or
second- degree relatives with seizures [24]. In Ituri, evidence of a significant clustered distri-
bution of households with family members with epilepsy compared to those without epi-
lepsy was observed. This aligns with observations from other onchocerciasis endemic areas
[25] and most likely reflects shared exposure to infective bites of the local vector(s). The fact
that only a relevant epilepsy cluster was observed in the Logo Health zone in Ituri may be
because this was also the only zone, included in the survey, where in certain villages Iver-
mectin was never distributed. A (spatial) point process model in order to predict the risk
of epilepsy due to the infective vector density could be of interest. However, this was not
Table 4. Case control study: Ivermectin history according to epilepsy status, in health area, age and
gender matched case and control study univariate analysis, with a random effect for pair identity.
Factor Odds
Ratio
95% C.I. P
Value
Ivermectin received the year before epilepsy appeared (equivalent year in
the controls)
0.52 0.28,
0.98
0.04
Proportion of occasions, in years eligible, Ivermectin received before
epilepsy appearance (or equivalent period in controls)
0.46 0.22,
0.95
0.04
Proportion of occasions, in years eligible, Ivermectin received after
epilepsy appearance (or equivalent period in controls)
0.89 0.46,
1.70
0.71
https://doi.org/10.1371/journal.pntd.0005732.t004
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possible given the available data (sample locations were too irregular and clustered only in
specific areas).
Similar to the results of a previous small case control study performed in Titule (Bas-Uele),
the current case-control matched pairs analysis demonstrated that before the appearance of
Table 5. Multivariate regression analysis of individual risk factors for epilepsy.
Fixed effects Population in
sample
No. of patients
with epilepsy
Epilepsy
prevalence
OR (95%CI) P
Value
Proportion of Ivermectin doses received 2.04 1.21,
3.42
<0.01
Onchocerciasis associated skin lesions (leopard skin) Present 205 18 8.78% 4.57 2.34,
8.57
<0.001
Absent 12,131 388 0.32%
Interaction between proportion of Ivermectin doses received
and presence of Onchocerciasis associated skin lesions
(leopard skin)
0.08 0.003,
0.79
0.04
Age 0.99 0.98,
0.99
<0.001
Gender Male 6041 221 3.66% 1.27 1.03,
1.56
0.01
Female 6304 186 2.95%
Health area random effect1 0.31
Patient random effect2 0.54
1) Variance between random by-health area effect
2) Variance between random patient effect
https://doi.org/10.1371/journal.pntd.0005732.t005
Fig 4. Plot of the 2 most likely clusters of epilepsy cases for each province, based on Kulldorff’s scan statistics.
Each blue circle (seen here as overlapping due to close proximity) represents one household, regardless of the epilepsy
status.
https://doi.org/10.1371/journal.pntd.0005732.g004
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epilepsy, compared to the same life period in controls, persons with epilepsy had taken Iver-
mectin less frequently than controls. Considering the whole population, significant associa-
tions were identified between Ivermectin use, the presence of skin lesions and epilepsy status,
even with fixed factor controlled for age and gender. Among patients with leopard skin, those
who used Ivermectin were 84% less likely to have epilepsy than those who did not use Ivermec-
tin. Leopard skin is a clinical sign that indicates that the person has been heavily exposed to O.
v. and/or that the person did not take Ivermectin while infected with onchocerciasis. This find-
ing may indicate that also when infected with onchocerciasis Ivermectin may reduce the risk
for epilepsy. Among patients without leopard skin, those who used Ivermectin were twice
likely to have epilepsy as compared to those who did not use Ivermectin. This could be
explained by the fact that people use Ivermectin because of itching caused by onchocerciasis.
People know that the itching disappears with the intake of Ivermectin. In a previous study,
individuals reporting itching were more likely to be persons with epilepsy [6]. After the intake
of Ivermectin, microfilariae disappear from the skin together with the itching and people stop
scratching. Therefore, because of decreased scratch lesions and skin inflammation people tak-
ing Ivermectin are less likely to develop Leopard skin lesions but they are more likely to have
been infected with the O.v. parasite in the past and therefore are more likely to have epilepsy.
There are no arguments for suspecting that Ivermectin is able to cause seizures. Indeed, Iver-
mectin is not known to pass the blood brain barrier in humans. Only in certain dogs, collies
and Australian shepherds because of MDR1 polymorphism, Ivermectin is able to cause sei-
zures [26]. Ivermectin is rapidly absorbed. Therefore if Ivermectin could induce seizures, we
would expect to see the onset of these seizures shortly after the administration of the Ivermec-
tin. This was never reported despite the many millions of doses of Ivermectin that have been
distributed for more than 20 years. Moreover, there is anecdotal evidence that in persons with
onchocerciasis Ivermectin reduces the frequency of epilepsy [27]. In Aketi town, people were
very eager to receive Ivermectin even more than once a year because the drug was known to
reduce the itching and the community distributors treated themselves 3 to 4 times a year
(Tepage F, personal communication).
Our study has several limitations. In most individuals, epilepsy was only reported and not
observed. Only in the Makana health area (Tshopo) and Ituri (Logo and Rethy health areas),
were individuals with epilepsy examined by a neurologist (JMK). A second neurologist, Dr D
Mukendi recently visited the villages of Wela and Makoko and confirmed all the epilepsy cases
that were identified during the 2015 survey. Laboratory investigations, to identify the cause of
the epilepsy were not performed. In our definition of epilepsy, we did not specify a time limit
for laps between seizures, and we mainly included convulsive epilepsy. Therefore, comparison
of our results with published epilepsy prevalence data is difficult.
Additionally, the prevalence assessment was performed during short visits to the health
zone with no accompanying qualitative studies. As discussed above, the exact nature of the
relationship between Ivermectin use and epilepsy may be complex and as such it is likely to
require knowing why people were taking or not taking Ivermectin. The different epilepsy sur-
veys were performed with a similar methodology, however not always by the same research
team. Certain data obtained during the surveys may suffer from recall bias. For example even
age and age/year of onset of the epilepsy may be very imprecise. Questions could be raised
about the reliability of the history of Ivermectin use, in certain individuals over a period of
more than 10 years. Available REMO data are from 2003 and 2008 and are of little relevance
after many years of CDTI. Indeed in the epilepsy case control studies we performed in Tshopo
and Ituri a reduction in nodule carriers was observed.
In conclusion, the prevalence of epilepsy in villages in onchocerciasis endemic areas in the
DRC was 2–10 times higher than in non-onchocerciasis endemic regions in Africa. Our study
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confirms previous findings that epilepsy is associated with O.v. infestation. Our data suggests
that Ivermectin protects against epilepsy in an onchocerciasis endemic region. This finding
suggests that in onchocerciasis endemic regions, the physiopathology of the epilepsy character-
ized by seizures starting between the ages of 3 to 18 years, is triggered by the O.v. parasite.
Because microfilariae are not considered to invade the brain, the mechanism of this epilepsy
could be through an auto-immune mechanism as was recently proposed for nodding syn-
drome [28,29]. However, a prospective population-based intervention study, ideally with Iver-
mectin twice a year, is needed to confirm that indeed Ivermectin protects against epilepsy in
onchocerciasis endemic regions.
Supporting information
S1 Questionnaire. Questionnaire used for the prevalence survey.
(DOCX)
S1 Checklist. STROBE checklist.
(DOCX)
Acknowledgments
We thank Dr Mukendi for validating the diagnosis of epilepsy in the health zone of Aketi and
all the village health care workers for their assistance in carrying out the surveys and all the
families for their participation. The Belgian Technical Cooperation (CTB) office of Kinshasa is
acknowledged for the grant “Fonds de l’expertise EPIRIVE”. The Rotary Club of Seneffe, Mar-
iemont, Le Roeulx, La Louvière, Braine-Le-Chateau (Belgium), and Carvin (France) are
thanked for the district grant “Congo River” that donated five microscopes to health centres
and that were used during this study.
Author Contributions
Conceptualization: Bethany Levick, Anne Laudisoit, Floribert Tepage, Robert Colebunders.
Data curation: Anne Laudisoit, Floribert Tepage, Michel Mandro, Jean Marie Kashama, Alli-
ance Tagoto, Dadi Falay, Robert Colebunders.
Formal analysis: Bethany Levick, Anne Laudisoit, Chellafe Ensoy-Musoro, Caroline Bonareri
Osoro, Michael Begon.
Funding acquisition: Robert Colebunders.
Investigation: Anne Laudisoit, Floribert Tepage, Michel Mandro, Patrick Suykerbuyk, Michel
Komba, Robert Colebunders.
Methodology: Anne Laudisoit, Robert Colebunders.
Project administration: Anne Laudisoit, Patrick Suykerbuyk, Robert Colebunders.
Resources: Anne Laudisoit, Michel Komba, Robert Colebunders.
Software: Bethany Levick, Chellafe Ensoy-Musoro, Caroline Bonareri Osoro.
Supervision: Anne Laudisoit, Robert Colebunders.
Validation: Anne Laudisoit, Robert Colebunders.
Visualization: Bethany Levick, Anne Laudisoit, Robert Colebunders.
Writing – original draft: Bethany Levick, Anne Laudisoit, Robert Colebunders.
Epilepsy in onchocerciasis endemic regions in the Democratic Republic
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005732 July 14, 2017 12 / 14
Writing – review & editing: Bethany Levick, Anne Laudisoit, Floribert Tepage, Chellafe
Ensoy-Musoro, Michel Mandro, Caroline Bonareri Osoro, Patrick Suykerbuyk, Michel
Komba, Michael Begon.
References
1. Wamala JF, Malimbo M, Tepage F, Lukwago L, Okot CL, Cannon RO, Laudisoit A, Colebunders R
(2015) Nodding Syndrome May Be Only the Ears of the Hippo. PLoS Negl Trop Dis 9: e0003880.
https://doi.org/10.1371/journal.pntd.0003880 PMID: 26270048
2. Makenga Bof JC, Maketa V, Bakajika DK, Ntumba F, Mpunga D, Murdoch ME, Hopkins A, Noma MM,
Zoure H, Tekle AH, Katabarwa MN, Lutumba P (2015) Onchocerciasis control in the Democratic
Republic of Congo (DRC): challenges in a post-war environment. Trop Med Int Health 20: 48–62.
https://doi.org/10.1111/tmi.12397 PMID: 25302560
3. Weekly epidemiological record—Releve´ e´pide´miologique hebdomadaire (2016) 91th YEAR / 28 octo-
ber; No 43, 2016, 91, 501–516.
4. World Health Organization/African Programme for Onchocerciasis Control (WHO/APOC) (2007) Revi-
talising health care delivery in sub-Saharan Africa. The potential of community directed interventions to
strengthen health systems. 36p.
5. Colebunders R, Tepage F, Rood E, Mandro M, Abatih EN, Musinya G, Mambandu G, Kabeya J,
Komba M, Levick B, Mokili JL, Laudisoit A (2016) Prevalence of River Epilepsy in the Orientale Province
in the Democratic Republic of the Congo. PLoS Negl Trop Dis 10: e0004478. https://doi.org/10.1371/
journal.pntd.0004478 PMID: 27139245
6. Colebunders R, Mandro M, Mokili JL, Mucinya G, Mambandu G, Pfarr K, Reiter-Owona I, Hoerauf A,
Tepage F, Levick B, Begon M, Laudisoit A (2016) Risk factors for epilepsy in the Bas-Uele Province in
the Democratic Republic of the Congo: a case control study. Int J Infect Dis. https://doi.org/10.1016/j.
ijid.2016.05.018 PMID: 27210267
7. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr., Forsgren L, French
JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T,
Watanabe M, Wiebe S (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:
475–482. https://doi.org/10.1111/epi.12550 PMID: 24730690
8. Tekle AH, Zoure H, Wanji S, Leak S, Noma M, Remme JH, Amazigo U (2011) Integrated rapid mapping
of onchocerciasis and loiasis in the Democratic Republic of Congo: impact on control strategies. Acta
Trop 120 Suppl 1: S81–S90.; https://doi.org/10.1016/j.actatropica.2010.05.008 PMID: 20525531
9. Diagana M, Preux PM, Tuillas M, Ould HA, Druet-Cabanac M (2006) [Depistage de l’epilepsie en zones
tropicales: validation d’un questionnaire en Mauritanie]. Bull Soc Pathol Exot 99: 103–107. PMID:
16821440
10. Kulldorff M. (1997) A spatial scan statistic. Communications in Statistics: Theory and Methods.
26:1487–1496. https://www.satscan.org/
11. R Core Team (2016) R: A language and environment for statistical computing. R Foundation for Statis-
tical Computing, Vienna, Austria. URL http://www.R-project.org/.
12. Pinheiro JC (2017) Package "nlme". 336p. https://cran.r-project.org/web/packages/nlme/nlme.pdf
13. WHO (2010) Cadre conceptuel et ope´rationnel de l’e´limination de l’onchocercose par le traitement à
l’ivermectine.WHO/APOC/MG/10.1. 24p. http://who.int/apoc/oncho_elimination_report_french.pdf
14. Pion SD, Kaiser C, Boutros-Toni F, Cournil A, Taylor MM, Meredith SE, Stufe A, Bertocchi I, Kipp W,
Preux PM, Boussinesq M (2009) Epilepsy in onchocerciasis endemic areas: systematic review and
meta-analysis of population-based surveys. PLoS Negl Trop Dis 3: e461. https://doi.org/10.1371/
journal.pntd.0000461 PMID: 19529767
15. Edwards T, Scott AG, Munyoki G, Odera VM, Chengo E, Bauni E, Kwasa T, Sander LW, Neville BG,
Newton CR (2008) Active convulsive epilepsy in a rural district of Kenya: a study of prevalence and pos-
sible risk factors. Lancet Neurol 7: 50–56. https://doi.org/10.1016/S1474-4422(07)70292-2 PMID:
18068520
16. Forsgren L (2008) Estimations of the prevalence of epilepsy in sub-Saharan Africa. Lancet Neurol 7:
21–22. https://doi.org/10.1016/S1474-4422(07)70295-8 PMID: 18068521
17. Kamuyu G, Bottomley C, Mageto J, Lowe B, Wilkins PP, Noh JC, Nutman TB, Ngugi AK, Odhiambo R,
Wagner RG, Kakooza-Mwesige A, Owusu-Agyei S, Ae-Ngibise K, Masanja H, Osier FH, Odermatt P,
Newton CR (2014) Exposure to multiple parasites is associated with the prevalence of active convulsive
epilepsy in sub-Saharan Africa. PLoS Negl Trop Dis 8: e2908. https://doi.org/10.1371/journal.pntd.
0002908 PMID: 24875312
Epilepsy in onchocerciasis endemic regions in the Democratic Republic
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005732 July 14, 2017 13 / 14
18. Paul A, Adeloye D, George-Carey R, Kolcic I, Grant L, Chan KY (2012) An estimate of the prevalence of
epilepsy in Sub-Saharan Africa: A systematic analysis. J Glob Health 2: 020405. https://doi.org/10.
7189/jogh.02.020405 PMID: 23289080
19. Preux PM, Druet-Cabanac M (2005) Epidemiology and aetiology of epilepsy in sub-Saharan Africa.
Lancet Neurol 4: 21–31. https://doi.org/10.1016/S1474-4422(04)00963-9 PMID: 15620854
20. Kariuki SM, White S, Chengo E, Wagner RG, Ae-Ngibise KA, Kakooza-Mwesige A, Masanja H, Ngugi
AK, Sander JW, Neville BG, Newton CR (2015) Electroencephalographic features of convulsive epi-
lepsy in Africa: A multicentre study of prevalence, pattern and associated factors. Clin Neurophysiol.
https://doi.org/10.1016/j.clinph.2015.07.033 PMID: 26337840
21. Kaiser C, Pion SD, Boussinesq M (2013) Case-control studies on the relationship between onchocerci-
asis and epilepsy: systematic review and meta-analysis. PLoS Negl Trop Dis 7: e2147. https://doi.org/
10.1371/journal.pntd.0002147 PMID: 23556028
22. Ovuga E, Kipp W, Mungherera M, Kasoro S (1992) Epilepsy and retarded growth in a hyperendemic
focus of onchocerciasis in rural western Uganda. East Afr Med J 69: 554–556. PMID: 1473507
23. Colebunders R, Irani J, Post R (2016) Nodding syndrome—we can now prevent it. Int J Infect Dis. Mar;
44:61–3. https://doi.org/10.1016/j.ijid.2016.01.016 PMID: 26845444
24. Sozmen V, Baybas S, Dirican A, Koksal A, Ozturk M (2011) Frequency of epilepsies in family members
of patients with different epileptic syndromes. Eur Neurol 65: 4–9. https://doi.org/10.1159/000322125
PMID: 21109740
25. Colebunders R, Hendy A, Mokili JL, Wamala JF, Kaducu J, Kur L, Tepage F, Mandro M, Mucinya G,
Mambandu G, Komba MY, Lumaliza JL, van OM, Laudisoit A (2016) Nodding syndrome and epilepsy in
onchocerciasis endemic regions: comparing preliminary observations from South Sudan and the Demo-
cratic Republic of the Congo with data from Uganda. BMC Res Notes 9: 182. https://doi.org/10.1186/
s13104-016-1993-7 PMID: 27005304
26. Mealey KL (2004) Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther. Oct; 27(5):257–
64. Review
27. Kipp W, Burnham G, Kamugisha J (1992) Improvement in seizures after ivermectin. Lancet 26; 340
(8822):789–90.
28. Johnson TP, Tyagi R, Lee PR, Lee MH, Johnson KR, Kowalak J, Elkahloun A, Medynets M, Hategan A,
Kubofcik J, Sejvar J, Ratto J, Bunga S, Makumbi I, Aceng JR, Nutman TB, Dowell SF, Nath A (2017)
Nodding syndrome may be an autoimmune reaction to the parasitic worm Onchocerca volvulus. Sci
Transl Med. Feb 15; 9(377). pii: eaaf6953. https://doi.org/10.1126/scitranslmed.aaf6953 PMID:
28202777
29. Colebunders R, Titulaer MJ (2017) Nodding syndrome: Preventable and treatable. Sci Transl Med. Feb
15; 9(377).
Epilepsy in onchocerciasis endemic regions in the Democratic Republic
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005732 July 14, 2017 14 / 14
